Terms: = Lung cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
9466 results:
1. Decoding dynamic interactions between egfr-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract] [Full Text] [Related]
2. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract] [Full Text] [Related]
3. Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell lung cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.
Moulson R; Law J; Sacher A; Liu G; Shepherd FA; Bradbury P; Eng L; Iczkovitz S; Abbie E; Elia-Pacitti J; Ewara EM; Mokriak V; Weiss J; Pettengell C; Leighl NB
Curr Oncol; 2024 Apr; 31(4):1947-1960. PubMed ID: 38668049
[TBL] [Abstract] [Full Text] [Related]
4. Gefitinib Induces Apoptosis in NSCLC Cells by Promoting Glutaminolysis and Inhibiting the MEK/ERK Signaling Pathway.
Zhang Y; Liu H; Liu X; Lang L
Discov Med; 2024 Apr; 36(183):836-841. PubMed ID: 38665031
[TBL] [Abstract] [Full Text] [Related]
5. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
7. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell lung cancer Treated with PD-1/PD-L1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
8. egfr Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell lung cancer.
Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
[TBL] [Abstract] [Full Text] [Related]
9. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
10. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in egfr mutant lung cancer.
Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation.
Gao E; Wang Y; Fan GL; Xu G; Wu ZY; Liu ZJ; Liu JC; Mao LF; Hou X; Li S
Sci Rep; 2024 Apr; 14(1):9223. PubMed ID: 38649732
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant egfr-TKI therapy in Non-Small cell lung cancer.
Grant C; Nagasaka M
Cancer Treat Rev; 2024 May; 126():102724. PubMed ID: 38636443
[TBL] [Abstract] [Full Text] [Related]
14. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
15. Bioinformatics-driven discovery of novel egfr kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
Radwan AA; Alanazi F; Al-Dhfyan A
PLoS One; 2024; 19(4):e0298326. PubMed ID: 38625872
[TBL] [Abstract] [Full Text] [Related]
16. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
[TBL] [Abstract] [Full Text] [Related]
17. A Path to Persistence after egfr Inhibition.
Rumde PH; Burns TF
Cancer Res; 2024 Apr; 84(8):1188-1190. PubMed ID: 38616658
[TBL] [Abstract] [Full Text] [Related]
18. Mobocertinib in Patients with egfr Exon 20 Insertion-Positive Non-Small Cell lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
19. egfr degraders in non-small-cell lung cancer: Breakthrough and unresolved issue.
Shen J; Chen L; Liu J; Li A; Zheng L; Chen S; Li Y
Chem Biol Drug Des; 2024 Apr; 103(4):e14517. PubMed ID: 38610074
[TBL] [Abstract] [Full Text] [Related]
20. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without egfr or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
[Next]
